Astrazeneca Paying up to $440M For Payload Tech Firm Spirogen
LONDON – Astrazeneca plc is taking a giant stride into antibody-drug conjugates (ADCs), acquiring payload technology company Spirogen plc for $200 million in cash, with a further $240 million to come in potential development milestones.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter